Profile data is unavailable for this security.
About the company
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
- Revenue in USD (TTM)88.55m
- Net income in USD-157.85m
- Incorporated2015
- Employees181.00
- LocationKymera Therapeutics Inc500 North Beacon Street, 4Th FloorWATERTOWN 02472United StatesUSA
- Phone+1 (857) 285-5314
- Fax+1 (302) 655-5049
- Websitehttps://www.kymeratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc | 319.12m | 169.95m | 2.64bn | 125.00 | 17.41 | 4.98 | 15.83 | 8.48 | 2.64 | 2.64 | 5.22 | 9.21 | 0.6825 | -- | 449.46 | 2,849,286.00 | 36.35 | -35.90 | 39.20 | -41.36 | -- | -- | 53.26 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| SpringWorks Therapeutics Inc | 86.19m | -301.06m | 2.64bn | 305.00 | -- | 4.71 | -- | 30.46 | -4.44 | -4.44 | 1.25 | 7.50 | 0.1519 | -- | -- | 282,577.10 | -53.07 | -36.97 | -57.99 | -39.49 | 95.27 | -- | -349.32 | -2,176.46 | 7.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| ACADIA Pharmaceuticals Inc | 890.53m | 30.57m | 2.71bn | 630.00 | 90.56 | 5.27 | 64.81 | 3.06 | 0.1813 | 0.1813 | 5.38 | 3.12 | 1.14 | 1.83 | 9.60 | 1,491,682.00 | 3.93 | -27.50 | 5.93 | -32.73 | 91.72 | 95.62 | 3.43 | -38.35 | 1.95 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Geron Corp | 1.37m | -219.55m | 2.72bn | 141.00 | -- | 9.29 | -- | 2,081.03 | -0.3595 | -0.3595 | 0.0023 | 0.5103 | 0.0032 | -- | 0.6367 | 9,737.59 | -50.78 | -51.32 | -63.77 | -64.90 | 63.00 | -- | -15,990.60 | -19,949.13 | 3.60 | -- | 0.2139 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| PTC Therapeutics, Inc. | 900.45m | -479.52m | 2.73bn | 988.00 | -- | -- | -- | 3.09 | -6.32 | -6.32 | 11.84 | -12.75 | 0.5534 | 2.16 | 4.94 | 911,390.70 | -29.47 | -26.71 | -44.23 | -33.46 | 92.35 | 93.94 | -53.25 | -83.80 | 2.17 | -1.16 | 1.70 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Celldex Therapeutics, Inc. | 8.30m | -150.22m | 2.77bn | 160.00 | -- | 3.35 | -- | 328.64 | -2.74 | -2.74 | 0.1481 | 12.28 | 0.0145 | -- | 10.05 | 51,887.50 | -26.24 | -29.65 | -27.27 | -31.42 | -- | -- | -1,809.40 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Ideaya Biosciences Inc | 11.96m | -153.74m | 2.94bn | 124.00 | -- | 2.88 | -- | 249.21 | -2.18 | -2.18 | 0.1718 | 12.24 | 0.0159 | -- | 148.57 | 96,451.61 | -20.48 | -19.17 | -21.42 | -21.05 | -- | -- | -1,285.44 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Kymera Therapeutics Inc | 88.55m | -157.85m | 2.99bn | 181.00 | -- | 4.41 | -- | 35.66 | -2.41 | -2.41 | 1.36 | 11.12 | 0.1258 | -- | 30.40 | 473,529.40 | -22.42 | -23.03 | -24.45 | -27.64 | -- | -- | -178.27 | -207.82 | -- | -- | 0.0028 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -199.06m | 3.04bn | 251.00 | -- | 3.66 | -- | -- | -2.74 | -2.74 | 0.00 | 11.15 | 0.00 | -- | -- | 0.00 | -25.38 | -20.71 | -26.37 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Guardant Health Inc | 643.81m | -490.76m | 3.09bn | 1.78k | -- | -- | -- | 4.85 | -4.09 | -4.09 | 5.36 | -0.0131 | 0.3733 | 4.04 | 6.89 | 361,894.30 | -28.46 | -22.26 | -32.21 | -24.59 | 59.95 | 64.62 | -76.23 | -97.07 | 6.07 | -10.18 | 1.00 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Iovance Biotherapeutics Inc | 32.77m | -440.22m | 3.09bn | 557.00 | -- | 4.00 | -- | 95.86 | -1.68 | -1.68 | 0.1245 | 2.59 | 0.0381 | 2.40 | 2.07 | 58,836.63 | -51.14 | -51.47 | -57.20 | -57.56 | -37.43 | -- | -1,343.27 | -137,873.80 | 4.85 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.12bn | 91.00 | -- | 3.88 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 455.66m | -119.54m | 3.24bn | 517.00 | -- | 24.60 | -- | 7.16 | -0.397 | -0.397 | 1.51 | 0.4471 | 0.6159 | 0.6948 | 6.12 | 881,344.30 | -16.16 | -30.65 | -20.75 | -36.55 | 89.88 | 88.94 | -26.23 | -86.10 | 2.26 | -0.6134 | 0.7459 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Rhythm Pharmaceuticals Inc | 101.78m | -260.73m | 3.28bn | 226.00 | -- | 84.71 | -- | 32.76 | -4.37 | -4.37 | 1.71 | 2.94 | 0.2943 | 1.25 | 6.48 | 450,367.30 | -75.00 | -47.21 | -87.80 | -52.84 | 88.80 | -- | -254.88 | -681.38 | 6.31 | -- | 0.3765 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Alvotech SA | 308.73m | -618.38m | 3.34bn | 999.00 | -- | -- | -- | 10.92 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Kymera Therapeutics Inc's reporting currency: US Dollar USD
68.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 6.31m | 9.90% |
| Baker Bros. Advisors LPas of 21 Aug 2024 | 6.00m | 9.41% |
| BVF Partners LPas of 20 Aug 2024 | 5.16m | 8.10% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 4.83m | 7.57% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.69m | 7.36% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 4.19m | 6.58% |
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 3.89m | 6.10% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.50m | 5.49% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 3.01m | 4.71% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.91m | 3.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
